MCRB
MCRB clinical trials: Seres Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Seres Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 8
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MCRB on the catalyst calendar · MCRB registry changes
- Primary completion Jul 23, 2024ActualPhase 1NCT04995653A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCTSeres Therapeutics, Inc. · Allogeneic Hematopoietic Stem Cell TransplantationCompletedMCRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT02437500Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)Seres Therapeutics, Inc. · Clostridioides Difficile InfectionApproved for marketingMCRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2022ActualPhase 3NCT03183141ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile InfectionSeres Therapeutics, Inc. · Clostridioides Difficile InfectionCompletedMCRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 3, 2020ActualPhase 3NCT03183128ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile InfectionSeres Therapeutics, Inc. · Clostridium Difficile InfectionCompletedMCRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2018ActualPhase 1NCT02830542SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent RecurrenceSeres Therapeutics, Inc. · Clostridium Difficile InfectionCompletedMCRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2021ActualPhase 2NCT03759041A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative ColitisSeres Therapeutics, Inc. · Ulcerative ColitisTerminatedMCRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 6, 2017ActualPhase 1NCT02618187A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative ColitisSeres Therapeutics, Inc. · Ulcerative ColitisCompletedMCRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualPhase 2NCT02437487SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)Seres Therapeutics, Inc. · Clostridium DifficileCompletedMCRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2022ActualPhase 1NCT03817125Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome InterventionParker Institute for Cancer Immunotherapy · Metastatic MelanomaCompletedMCRBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner